The two-page center spread from Sunday’s New York Times, featuring more than 70 Civic Alliance member company CEOs who’ve made strong commitments to be “100% In for democracy.”

Elektra Labs has joined the Civic Alliance. I’ll share more about what this means for our team, but first, a personal story.

I was catching up with my sister, who has serve as a poll worker in Detroit. I learned that the US is facing a record shortage of poll workers this year because:

  • most poll workers are >60 years old
  • fewer of them are signing up due to the risk of contracting COVID

This means that younger folks will need to step in and volunteer to ensure a safe, healthy, and trusted election this fall. …


We’re pleased to announce that Dena Mendelsohn has joined Elektra Labs.

At the heart of what we do at Elektra is to assess the novel benefits and risks that connected technologies pose to people. One of the emerging risks involves data rights and governance. The advantages of connected health technologies do not have to come at the expense of privacy. Yet that is often the false choice forced on users. Dena has been at the forefront of this movement, outlining these trade-offs and highlighting them particularly to those less informed about systemic shift. …


We’re pleased to announce that Tristan Rasmussen has joined Elektra Labs.

As the COVID-19 outbreak continues to unfold, our team at Elektra has adapted our remote monitoring at home work to broaden beyond pharma sponsors and clinical trials into telehealth and routine care. During his first few days with the team, Tristan jumped in with two feet into the project that we launched to support health during COVID-19, creating a new set of features for reports to evaluate different types of remote monitoring tools on ElektraLabs.com.

Tristan is joining our engineering team at Elektra. Formerly he was a Senior Software…


Today, we’re thrilled to share that nine esteemed healthcare and security professionals are joining Elektra Labs’ Strategic Advisory Board (SAB).

Our new board consists of:

Elektra Labs is working at the exciting multidisciplinary intersection of connected technologies, healthcare, security, data legal rights, and algorithms. To do this well, we need to collaborate with those who are able to shift between engineering, data science, clinical, security, ethical and legal issues. …


We’re pleased to announce that Mark Shervey has joined Elektra Labs.

We first met Mark through his work with the HD2I team at Mount Sinai and their work using connected technology to power N of 1 clinical research. We are honored to bring on his expertise to grow Elektra.

Prior to joining Elektra Labs, Mark was the Chief Architect for the Institute for Next Generation Healthcare at the Icahn School of Medicine at Mount Sinai (INGH), where he managed patient datasets, data integrations and led technology strategy at the institute. During his time at Mount Sinai, he represented INGH as…


We’re pleased to announce that Christine Manta has joined Elektra Labs.

We first met Christine through her work with the Clinical Trials Transformation Initiative (CTTI)’s systematic review of feasibility studies using mobile technologies in clinical research. We are honored to bring on her expertise to grow Elektra.

Prior to joining Elektra Labs, Christine has been involved in every phase of the research process including protocol development, IRB regulation and data management. While working at Christiana Care’s Value Institute, University of Pittsburgh Medical Center (UPMC) and Children’s Hospital of Philadelphia (CHOP), Christine covered a range of focus areas including health services…


A framework for “direct-to-patient,” “remote,” “site-less,” and “virtual” clinical research

A year ago, the Elektra Labs team published a piece on “Software-Enabled Clinical Trials” which mapped software tools that support clinical research. Since then, a number of new clinical trial approaches have emerged, and in the following piece we’ll decrypt some of the buzzwords from “site-less” to “direct-to-patient” to “virtual” and beyond.

We depend on clinical trials to bring safe and effective drugs and devices to market.

However, many of our life-altering drugs and devices are developed on limited populations in strict laboratory-controlled settings, which may not match natural settings. Over 70 percent of potential participants live more than 2…


A framework for “direct-to-patient,” “remote,” “site-less,” and “virtual” clinical research

A year ago, the Elektra Labs team published a piece on “Software-Enabled Clinical Trials” which mapped software tools that support clinical research. Since then, a number of new clinical trial approaches have emerged, and in the following piece we’ll decrypt some of the buzzwords from “site-less” to “direct-to-patient” to “virtual” and beyond.

We depend on clinical trials to bring safe and effective drugs and devices to market.

However, many of our life-altering drugs and devices are developed on limited populations in strict laboratory-controlled settings, which may not match natural settings. Over 70 percent of potential participants live more than 2…


Last month, the Twitterverse stumbled upon an all-too-common situation that is worth discussing in more than 280 characters. Deleting a Tweet is the deficient but only available option to stop the viral spread of incomplete information as new context arises. Twitter has a product design flaw that stunts productive conversations, and it’s time to lobby Twitter to make a change.

This is Part 2 in the series. In Part 1, we looked at the ‘side effects’ of an attention economy.

Last month, I posted a Tweet that went viral and garnered 1.7M+ impressions (see Part 1 for details). As more…


In the arms-race for attention, our online communication platforms employ nudges, notifications, and other tools to change our behavior and increase our “engagement.” Like drugs, algorithms also have (unintended) side-effects — stoking human anger, outrage and insecurities. In response, a new movement is digging into how to realign technology to serve humanity’s best interests.

Last month, I posted a quote and a question about Instagram’s emotional impact from an article in The Globe And Mail, a top newspaper in Canada.

Skim the full thread. There’s more than meets the eye.

Over 72 hours, the original Tweet garnered 1.7M+ impressions, Dopamine…

Andy Coravos

Starting a new adventure @ElektraLabs. Formerly at @AkiliLabs, @codeHBS, @KKR_Co, and @McKinsey. Digital Rights Advocate. #nonsibi

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store